UMN Pharma Initiates Phase I/II Trials for Influenza Vaccine
Posted on: Friday, 11 April 2008, 12:00 CDT
Japan based UMN Pharma has started the Phase I/II clinical trials for UMN-0501, the company's pandemic influenza vaccine.
Trials will begin in mid-June, 2008 followed by the completion of necessary investigations for an investigational new drug application (IND) filing as required by the PMDA (Pharmaceutical and Medical Devices Agency). The purpose of this clinical study is to assess the safety, efficacy and appropriate dose for the IND product in healthy adults aged 20-40.
Shuichi Kanazashi, president and CEO of UMN Pharma, said: "In response to the concerns about an increasing threat of pandemic influenza virus, we are developing UMN-0501 which will enable production of larger quantities of vaccine in a shorter period of time, and we will do our best to continue with the smooth implementation of clinical trials in order to provide a steady supply of UMN-0501 as soon as possible."
Source: Datamonitor
Related Articles
- PhotoThera Closes $50 Million Financing, Announces New President and Chief Executive Officer
- Protein Effects Of Hormone Replacement Therapy Uncovered
- Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
- Bostwick Wins Approval to Initiate Phase I/II Prostate Cancer Trial
- Pharmarama to Offer Comparator Drug Sourcing Services for Clinical Trials in China
- AST Hosts Comprehensive Clinical Trials Symposium
- ZIOPHARM Announces Interim Results in ZIO-101 Phase I Solid Tumor Cancer Trial; Clinical Activity in Several Cancers
- WorldHeart Expands RELIANT Trial Clinical Executive Committee
- New Brochure Helps Cancer Patients Understand Clinical Trials
 |
 |
User Comments (0)
RSS Feeds